Health · 1 sources covering this

Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/a0a54cb621b9e8bcafb72131b2ddc7279ef5c9da"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug"></iframe>

Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

How 1 sources are covering this

Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

More from Health

There's a global pandemic treaty that's signed -- and in 'limbo.' What's the holdup?

STAT+: Lilly wins approval for once-weekly insulin shot

STAT+: Up and down the ladder: The latest comings and goings

STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

More from Health

There's a global pandemic treaty that's signed -- and in 'limbo.' What's the holdup?

STAT+: Lilly wins approval for once-weekly insulin shot

STAT+: Up and down the ladder: The latest comings and goings

STAT+: Pharmalittle: We&#8217;re reading about a reticent FDA commish nominee, a Novo deal, and more

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more